2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:Tba6,Plaque psoriasis (PsO) is an inflammatory skin disease that can impair quality of life. Tildrakizumab, an anti-IL-23 p19 monoclonal antibody, offers a treatment option for patients eligible for systemic therapy or phototherapy, but real-world results have not been comprehensively analyzed. This systematic review and meta-analysis evaluated real-world effectiveness, quality-of-life impact, and safety of tildrakizumab for treatment of moderate-to-severe plaque PsO, alone and relative to guselkumab and risankizumab. MEDLINE® and Embase were searched on November 16, 2023, along with meeting abstracts (2021-2023) and bibliographies of previous reviews, for English-language real-world studies of tildrakizumab (singly or comparative) in adults with chronic moderate-to-severe plaque PsO. Outcomes included effectiveness (Psoriasis Area and Severity Index [PASI], Physician's Global Assessment [PGA], body surface area percentage [%BSA] affected), Dermatology Life Quality Index (DLQI), and safety (adverse events [AEs], serious AEs [SAEs], treatment-related AEs [TRAEs], or withdrawals due to AEs [WDAEs]). Meta-analyses were performed at 12-16, 24-28, and 36-52 weeks. Of 6982 records screened, 37 studies (45 publications) were analyzed. Tildrakizumab-treated patients experienced 78-87% improvement from baseline to 36-52 weeks across mean absolute PASI (12.81 [95% confidence interval 11.69, 13.92] to 1.62 [1.03, 2.20]), %BSA (16.21% [13.72%, 18.70%] to 3.27% [1.26%, 5.28%]), PGA (3.18 [2.89, 3.47] to 0.70 [0.08, 1.33]), and DLQI (14.59 [12.32, 16.87] to 1.83 [0.84, 2.82]), with low rates of AEs, SAEs, TRAEs, and WDAEs. Benefits and safety of tildrakizumab were similar to guselkumab and risankizumab. Tildrakizumab demonstrated effectiveness, with reduction from moderate-to-severe to mild disease and improved DLQI scores, without notable safety concerns, for up to 1 year in this real-world meta-analysis. Although real-world data must be interpreted cautiously because of heterogeneity and potential bias, these findings align with randomized trial results, further supporting the use of tildrakizumab in clinical practice. Plaque psoriasis is a chronic skin condition with several treatment options, including tildrakizumab, an antibody approved to treat moderate-to-severe plaque psoriasis in adults. The efficacy and safety of tildrakizumab were first established in clinical trials, but because clinical trials are conducted under ideal conditions, results in real-world practice may be different. This study reviewed and analyzed results from published studies outside of clinical trial settings. These real-world studies provide insight into how tildrakizumab works in everyday clinical practice. The findings from this study showed that tildrakizumab treatment is associated with continued effectiveness over time, improvements in skin-related quality of life, and no new or unexpected safety concerns in patients with moderate-to-severe plaque psoriasis.31:T4ef,Scott Gottlieb serves as a consultant and advisory board member for Bristol Myers Squibb, Janssen, Lilly, Sun Pharmaceutical Industries Limited, and UCB. Aaron S. Farberg has been an advisor for Amgen, Apogee, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Feldan, Galderma, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sun Pharma. Neal Bhatia is an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals. Mir Sohail Fazeli, Kimberly Hofer, and Otto Lam report employment with Evidinno Outcomes Research Inc. Victoria Barghout is CEO of Viver Health LLC, which receives funding from Bristol Myers Squibb, Novartis, Sun Pharma, and Taiho Pharmaceutical Co. Jacob Mathew reports employment with Sun Pharmaceutical Industries, Inc. Thomas J Ferro reports past employment with Sun Pharmaceutical Industries, Inc., and current employment with Data Loft, Inc.32:T710,Many biologic therapies are available for moderate-to-severe plaque psoriasis. A systematic literature review and network meta-analysis (NMA) was conducted to compare the efficacy of the interleukin (IL)-23 inhibitor, tildrakizumab, with other biologics at up to 28 weeks of treatment. The literature search was conducted on January 22, 2024, searching MEDLINE, Embase, and CENTRAL for randomized controlled trials (RCTs) investigating the comparative efficacy and safety of biologics in adult Asian patients with moderate-to-severe plaque psoriasis. NMAs were conducted for ≥ 75%, ≥ 90%, and 100% reduction in Psoriasis Area and Severity Index score (PASI 75, 90, and 100) and achieving a Physician Global Assessment (PGA) score of 0 or 1 after the induction period (12 and 16 weeks) and mid-term (28 weeks) follow-up. NMAs were conducted using the Bayesian framework outlined in the National Institute of Clinical Excellence guidelines. Nineteen RCTs conducted in China, Japan, Korea, and Taiwan with 11 different biologics were included. At Week 12, tildrakizumab had lower efficacy compared to other biologics. Between Weeks 12 and 28, the proportion of patients achieving PASI 75/90/100 with tildrakizumab increased from 60.77% to 81.84%, from 38.54% to 71.23%, and from 6.97% to 22.64%, respectively. At Week 28, tildrakizumab efficacy was comparable to other biologic therapies studied here, including tumor necrosis factor-alpha (TNFα), IL-17, IL-12/IL-23, and other IL-23 inhibitors. The efficacy of tildrakizumab improved over time, which underscores the importance of evaluating the sustained efficacy of tildrakizumab over the long term. Combined with low dosing frequency, tildrakizumab offers an effective treatment option for patients with moderate-to-severe plaque psoriasis.33:T760,ABSTRACTMany biologic therapies are available for moderate‐to‐severe plaque psoriasis. A systematic literature review and network meta‐analysis (NMA) was conducted to compare the efficacy of the interleukin (IL)‐23 inhibitor, tildrakizumab, with other biologics at up to 28 weeks of treatment. The literature search was conducted on January 22, 2024, searching MEDLINE, Embase, and CENTRAL for randomized controlled trials (RCTs) investigating the comparative efficacy and safety of biologics in adult Asian patients with moderate‐to‐severe plaque psoriasis. NMAs were conducted for ≥ 75%, ≥ 90%, and 100% reduction in Psoriasis Area and Severity Index score (PASI 75, 90, and 100) and achieving a Physician Global Assessment (PGA) score of 0 or 1 after the induction period (12 and 16 weeks) and mid‐term (28 weeks) follow‐up. NMAs were conducted using the Bayesian framework outlined in the National Institute of Clinical Excellence guidelines. Nineteen RCTs conducted in China, Japan, Korea, and Taiwan with 11 different biologics were included. At Week 12, tildrakizumab had lower efficacy compared to other biologics. Between Weeks 12 and 28, the proportion of patients achieving PASI 75/90/100 with tildrakizumab increased from 60.77% to 81.84%, from 38.54% to 71.23%, and from 6.97% to 22.64%, respectively. At Week 28, tildrakizumab efficacy was comparable to other biologic therapies studied here, including tumor necrosis factor‐alpha (TNFα), IL‐17, IL‐12/IL‐23, and other IL‐23 inhibitors. The efficacy of tildrakizumab improved over time, which underscores the importance of evaluating the sustained efficacy of tildrakizumab over the long term. Combined with low dosing frequency, tildrakizumab offers an effective treatment option for patients with moderate‐to‐severe plaque psoriasis.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"tildrakizumab: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on tildrakizumab (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/tildrakizumab\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"tildrakizumab\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/tildrakizumab\"}]}}"}}]],["$","$L2f",null,{"title":"tildrakizumab: Research & Clinical Takeaways","description":"Explore research on tildrakizumab (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0797","pmid":"42708646","title":"Current Evidence on IL-17 and IL-(12)/23 Inhibitor Safety during Pregnancy in Psoriasis: A Call for Harmonized Data Collection","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-09-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0797","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-12T06:20:17.230Z","updated_at":"2026-09-12T06:20:17.230Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Bimzelx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Siliq","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sample_size","value":"n=5962","value_numeric":5962},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Level of evidence assigned as 3 (systematic review of heterogeneous, mostly observational studies); no meta-analysis was conducted due to methodological heterogeneity.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Sex tag set to 'female' as the primary dataset covers maternal exposure; paternal exposure studies also exist but are a small subset (3 studies, 281 pregnancies).","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The review included all indications for IL inhibitors (not psoriasis-only), so findings may not be fully generalizable to psoriasis patients specifically.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The sample size (n=5,962) reflects maternal pregnancy exposures across all included studies, not a single trial cohort; the majority originated from pharmacovigilance databases with inherent reporting bias.","value_numeric":null}],"summaries":{"what_studied":"A PRISMA-compliant systematic literature review (search date May 2026) evaluated the reproductive safety of IL-12/23, IL-17, and IL-23 inhibitors during pregnancy and with paternal exposure in patients with psoriasis, examining pregnancy and neonatal outcomes across all available study designs.","key_result":"49 publications met inclusion criteria, reporting 5,962 pregnancies with maternal exposure; ustekinumab had the most data (2,933 pregnancies), followed by secukinumab (1,877), risankizumab (589), ixekizumab (296), guselkumab (217), tildrakizumab (32), bimekizumab (11), brodalumab (6), and mirikizumab (1). Cohort-level findings were generally reassuring — no consistent signal for adverse pregnancy or neonatal outcomes — except one study reporting increased risk of small-for-gestational-age infants with ustekinumab. Paternal exposure data were very limited (3 studies, 281 pregnancies).","limitations":"- Most exposures (n=5,074) came from pharmacovigilance databases that capture only adverse events, making incidence rates incalculable and meta-analysis infeasible.\n- Critical confounders (disease activity, exposure timing, comedications) were missing or unreported in the majority of studies; only one study used confounder-adjusted analysis.\n- Data were heavily skewed toward IBD patients, limiting psoriasis-specific and IL-17-specific conclusions.","practice_takeaway":"Available data are broadly reassuring but insufficient to issue definitive safety guidance; clinicians should weigh uncontrolled disease risk against medication uncertainty on a case-by-case basis. Existing psoriasis registries (e.g., BADBIR, BioCAPTURE) should add standardized pregnancy datasets to accelerate evidence generation."}},{"doi":"10.2340/actadv.v106.adv-2026-0593","pmid":"42658202","title":"A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-08-27T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0593","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-03T06:20:03.656Z","updated_at":"2026-09-03T06:20:03.656Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"brand","value":"Ilumetri","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"sample_size","value":"n=72","value_numeric":72},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"study_design","value":"Delphi Consensus Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"warning","value":"Down-titration recommendations are based solely on expert opinion; tildrakizumab-specific dose-reduction outcome data are lacking.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"warning","value":"Only 35 of 48 statements (73%) reached the predefined ≥75% consensus threshold, meaning several clinically important dosing scenarios—including all-patient initiation at 100 mg, prior IL-17 failure, and cardiometabolic syndrome—did not achieve consensus.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"warning","value":"The study included only European dermatologists; applicability to other regions or healthcare systems is uncertain.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"warning","value":"This is an expert consensus (Delphi) study funded by Almirall (tildrakizumab manufacturer); all steering group members received honoraria, which may introduce bias despite stated safeguards.","value_numeric":null}],"summaries":{"what_studied":"A modified Delphi study surveyed 72 experienced European dermatologists across 9 countries to build pan-European consensus on when to initiate, up-titrate, or down-titrate tildrakizumab 100 mg vs. 200 mg in adults with moderate-to-severe plaque psoriasis. Consensus was predefined as ≥75% agreement across 48 statements.","key_result":"Consensus was reached on 35 of 48 statements (73%). Strong agreement supported: 100 mg for weight <90 kg + BMI <25, moderate disease (PASI >5–<16, DLQI >5–<10), or biologic-naïve patients; 200 mg for weight ≥90 kg and/or BMI ≥25 (both 97%), severe disease (PASI ≥16, 89%), prior IL-23p19 inhibitor failure (78%), or ≥2 biologic failures (76%). Up-titration to 200 mg was supported for partial response (PASI ≥2) after 24–28 weeks (93%) or itch NRS >4 (93%); down-titration to 100 mg was supported after ≥1 year of PASI 100 remission on 200 mg (93%).","limitations":"- Convenience sampling across 9 countries limits generalizability beyond represented European healthcare settings.\n- Biologic failure was not precisely defined, and severity thresholds for high-impact areas were left undefined.\n- Consensus recommendations are not validated against clinical outcomes and require prospective confirmation.","practice_takeaway":"Start tildrakizumab at 100 mg in biologic-naïve patients with moderate disease and weight <90 kg/BMI <25; use 200 mg upfront in heavier, sicker, or biologic-experienced patients. Consider up-titration to 200 mg if PASI ≥2 persists at 24–28 weeks, and down-titration to 100 mg after ≥1 year of complete remission."}},{"doi":"10.1007/s13555-026-01809-8","pmid":"42262459","title":"New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-06-09T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01809-8","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-15T13:21:49.802Z","updated_at":"2026-06-15T13:21:49.802Z","tags":[{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"brand","value":"Ilumya","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"condition","value":"Latent Tuberculosis Infection","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"sample_size","value":"n=41","value_numeric":41},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"study_design","value":"Systematic Literature Review","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"warning","value":"Sample size tag reflects number of studies (41), not individual patients, as total patient-level N was not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"warning","value":"The 'impact_flag' of practice_changing is applied cautiously — the review's conclusion that routine LTBI screening may not be required contradicts current guidelines for many biologics, and this is based on indirect/safety-as-secondary evidence rather than dedicated TB-outcome trials.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"warning","value":"The review included case series and observational studies alongside RCTs; study quality is heterogeneous (assessed via RoB2 and NOS tools).","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"warning","value":"The single LTBI reactivation event in a risankizumab-treated patient was reported in one observational study; the abstract does not provide clinical details (e.g., TB prophylaxis status, country), limiting interpretation.","value_numeric":null}],"summaries":{"what_studied":"This systematic literature review evaluated the risk of latent TB infection (LTBI) reactivation and new TB infections in adults with psoriasis (PsO) or psoriatic arthritis (PsA) treated with IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), with a focus on the Asia-Pacific (APAC) region; 58 publications from 41 studies were included.","key_result":"No LTBI reactivation or new TB cases were observed in 33 of 34 PsO studies and all 8 PsA studies; only one observational study reported a single LTBI reactivation event in a risankizumab-treated PsO patient, including among patients with LTBI who did not complete chemoprophylaxis.","limitations":"- Most included studies were not designed with TB as a primary endpoint, limiting detection sensitivity.\n- Heterogeneous LTBI screening practices across studies and regions reduce comparability.\n- APAC-specific data came from only 9 publications across 8 studies, limiting conclusions for high-TB-burden settings.","practice_takeaway":"IL-23 inhibitors appear to carry minimal TB risk in patients with PsO or PsA, including those with LTBI who have not completed chemoprophylaxis. Routine pre-treatment LTBI screening before starting IL-23 inhibitor therapy may not be necessary, particularly in low-TB-prevalence regions."}},{"doi":"10.1007/s13555-026-01774-2","pmid":"42105056","title":"Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-05-09T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01774-2","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-14T13:22:44.638Z","updated_at":"2026-05-14T13:22:44.638Z","tags":[{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"brand","value":"Ilumya","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"condition","value":"Scalp Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"sample_size","value":"n=171","value_numeric":171},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"study_design","value":"Randomized Controlled Trial (Subgroup Analysis)","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"warning","value":"Brand name 'Ilumya' used; tildrakizumab is also marketed as 'Ilumetri' in some regions — clinicians should verify local brand names.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"warning","value":"Sample size tag reflects the modified intention-to-treat (mITT) population (n=171); the full ITT population was n=231. The subgroup Ns are smaller and vary by analysis.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"warning","value":"The study used only the 100 mg dose of tildrakizumab; some guidelines recommend 200 mg for patients with obesity, so generalizability to higher-dose decisions is limited.","value_numeric":null}],"summaries":{"what_studied":"This subgroup analysis of a Phase 3b randomized, double-blind, placebo-controlled trial examined whether obesity (BMI ≥30 vs. <30 kg/m²) affects the efficacy and safety of tildrakizumab 100 mg for moderate-to-severe scalp psoriasis in adults over 52 weeks (NCT03897088, conducted in the USA and Australia).","key_result":"At Week 16, tildrakizumab significantly outperformed placebo regardless of obesity status: IGA mod 2011 (scalp) response was achieved by 48.8% (obese) vs. 10.0% (placebo) and 50.0% (non-obese) vs. 4.8% (placebo); PSSI 90 response was 62.8% (obese) vs. 10.0% (placebo) and 58.7% (non-obese) vs. 0.0% (placebo). No statistically significant difference in efficacy or safety was found between patients with vs. without obesity through Week 52.","limitations":"- Subgroup analysis was not prospectively powered to detect differences between obesity groups, limiting conclusions about effect modification.\n- Relatively small subgroup sizes (obese on tildrakizumab: n=43; non-obese: n=46) reduce precision.\n- Only tildrakizumab 100 mg was studied; results may not extend to the 200 mg dose used in heavier patients in other trials.","practice_takeaway":"Tildrakizumab 100 mg appears effective and safe for scalp psoriasis in patients with obesity, with response rates comparable to non-obese patients through 52 weeks. Clinicians need not expect meaningfully reduced efficacy in obese patients treated with this agent for scalp disease."}},{"doi":"10.1007/s13555-025-01625-6","pmid":"41501565","title":"Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-01-08T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-025-01625-6","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-10","doi":"10.1007/s13555-025-01625-6","days":"7","issn":"2193-8210","rank":"8","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1007/s13555-025-01625-6","title":"Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis.","journal":"Dermatology and therapy","methods":"","results":"Of 6982 records screened, 37 studies (45 publications) were analyzed. Tildrakizumab-treated patients experienced 78-87% improvement from baseline to 36-52 weeks across mean absolute PASI (12.81 [95% confidence interval 11.69, 13.92] to 1.62 [1.03, 2.20]), %BSA (16.21% [13.72%, 18.70%] to 3.27% [1.26%, 5.28%]), PGA (3.18 [2.89, 3.47] to 0.70 [0.08, 1.33]), and DLQI (14.59 [12.32, 16.87] to 1.83 [0.84, 2.82]), with low rates of AEs, SAEs, TRAEs, and WDAEs. Benefits and safety of tildrakizumab were similar to guselkumab and risankizumab.","abstract":"$30","keywords":["Effectiveness","Psoriasis","Quality of life","Real-world evidence","Safety","Systematic review","Tildrakizumab"],"pubmed_id":"41501565","conclusions":"Tildrakizumab demonstrated effectiveness, with reduction from moderate-to-severe to mild disease and improved DLQI scores, without notable safety concerns, for up to 1 year in this real-world meta-analysis. Although real-world data must be interpreted cautiously because of heterogeneity and potential bias, these findings align with randomized trial results, further supporting the use of tildrakizumab in clinical practice.","publication_date":"2026-01-08T00:00:00"},"crossref":{"DOI":"10.1007/s13555-025-01625-6","URL":"https://doi.org/10.1007/s13555-025-01625-6","ISSN":["2193-8210","2190-9172"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01625-6.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s13555-025-01625-6","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01625-6.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis"],"author":[{"given":"Scott","family":"Gottlieb","sequence":"first","affiliation":[]},{"given":"Aaron S.","family":"Farberg","sequence":"additional","affiliation":[]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[]},{"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[]},{"given":"Kimberly","family":"Hofer","sequence":"additional","affiliation":[]},{"given":"Otto","family":"Lam","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Barghout","sequence":"additional","affiliation":[]},{"given":"Jacob","family":"Mathew","sequence":"additional","affiliation":[]},{"given":"Thomas J.","family":"Ferro","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100013671","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,7]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T16:11:01Z","timestamp":1767802261000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T20:04:27Z","timestamp":1767816267791,"date-parts":[[2026,1,7]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s13555-025-01625-6"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"31 October 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"5 December 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"7 January 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"},"order":2,"value":"$31"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"},"order":3,"value":"This article is based on previously conducted studies and does not include any new studies with human participants or animals performed by any of the authors."}],"deposited":{"date-time":"2026-01-07T17:01:40Z","timestamp":1767805300000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":null,"key":"1625_CR1","year":"2013","issue":"9","author":"N Weigle","volume":"87","first-page":"626","unstructured":"Weigle N, McBane S. Psoriasis. Am Fam Phys. 2013;87(9):626–33.","article-title":null,"journal-title":"Am Fam Phys","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2008.02.039","key":"1625_CR2","year":"2008","issue":"5","author":"A Menter","volume":"58","first-page":"826","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/nature05663","key":"1625_CR3","year":"2007","issue":"7130","author":"MA Lowes","volume":"445","first-page":"866","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73.","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.11.057","key":"1625_CR4","year":"2019","issue":"4","author":"A Menter","volume":"80","first-page":"1029","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ILUMYA® (tildrakizumab-asmn) injection, for subcutaneous use. Full Prescribing Information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(17)31279-5","key":"1625_CR6","year":"2017","issue":"10091","author":"K Reich","volume":"390","first-page":"276","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-022-00793-z","key":"1625_CR7","year":"2022","issue":"10","author":"D Thaçi","volume":"12","first-page":"2325","unstructured":"Thaçi D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325–41.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"European Medicines Agency. Ilumetri. 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri. Accessed 30 September 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1080/09546634.2017.1422591","key":"1625_CR9","year":"2018","issue":"6","author":"J Bilal","volume":"29","first-page":"569","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569–78.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1155/2019/2546161","key":"1625_CR10","year":"2019","issue":null,"author":"F Bai","volume":"2019","first-page":"2546161","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, Tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.","article-title":null,"journal-title":"J Immunol Res","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.4029","key":"1625_CR11","year":"2020","issue":"3","author":"AW Armstrong","volume":"156","first-page":"258","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–69.","article-title":null,"journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-022-02065-w","key":"1625_CR12","year":"2022","issue":"5","author":"CL Leonardi","volume":"39","first-page":"2256","unstructured":"Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256–69.","article-title":null,"journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for systematic reviews of interventions version 6.4 (updated 2023 August): Oxford: The Cochrane Collaboration; 2020. www.training.cochrane.org/handbook. Accessed 30 Sept 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1136/bmj.n71","key":"1625_CR14","year":"2021","issue":null,"author":"MJ Page","volume":"372","first-page":"n71","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","article-title":null,"journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2014. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 30 Sept 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Joanna Briggs Institute. Critical appraisal tools: checklist for analytical cross-sectional studies 2022. https://jbi.global/critical-appraisal-tools. Accessed 30 Sept 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/1741-7015-12-93","key":"1625_CR17","year":"2014","issue":null,"author":"S Cope","volume":"12","first-page":"93","unstructured":"Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:93.","article-title":null,"journal-title":"BMC Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR18","year":"2023","issue":null,"author":"JJ Deeks","volume":null,"first-page":null,"unstructured":"Deeks JJ, Higgins JPT. Chapter 10 Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions. UK: Cochrane Statistical Methods Group; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s00266-022-02977-6","key":"1625_CR19","year":"2023","issue":"suppl 1","author":"Y Chen","volume":"47","first-page":"83","unstructured":"Chen Y, Chen D, Wang Y, Han Y. Using Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Aesth Plast Surg. 2023;47(suppl 1):83–4.","article-title":null,"journal-title":"Aesth Plast Surg","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.15228","key":"1625_CR20","year":"2022","issue":"2","author":"A Narcisi","volume":"35","first-page":"e15228","unstructured":"Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-022-00722-y","key":"1625_CR21","year":"2022","issue":"6","author":"T Torres","volume":"23","first-page":"891","unstructured":"Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904.","article-title":null,"journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR22","year":"2023","issue":null,"author":"BB Bris","volume":null,"first-page":null,"unstructured":"Bris BB, De la Fuente H, del Mar Llamas Velasco M, et al. Polymorphism study as biomarkers of response to tildrakizumab. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR23","year":"2023","issue":null,"author":"A Downs","volume":null,"first-page":null,"unstructured":"Downs A, Barea A, Cammish G, et al. Real-world effectiveness of tildrakizumab in a UK cohort: a drug survival analysis. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2022.06.141","key":"1625_CR24","year":"2022","issue":"suppl 3","author":"N Kahen","volume":"87","first-page":"AB27","unstructured":"Kahen N, Ali Y, West DP. Cerebrovascular accident events associated with IL-23 inhibition: pharmacovigilance analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) from the RADAR (Research on Adverse Drug Events And Reports) program. J Am Acad Dermatol. 2022;87(suppl 3):AB27.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR25","year":"2023","issue":null,"author":"L Burzi","volume":null,"first-page":null,"unstructured":"Burzi L, Mastorino L, Dapavo P, Ribero S, Quaglino P. Psoriasis of the scalp, genital area, and palmoplantar psoriasis: efficacy of modern biologics drugs in difficult-to-treat areas. Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s13555-022-00800-3","key":"1625_CR26","year":"2022","issue":"10","author":"G Becher","volume":"12","first-page":"2343","unstructured":"Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343–54.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19468","key":"1625_CR27","year":"2023","issue":"12","author":"S Berenguer-Ruiz","volume":"37","first-page":"2517","unstructured":"Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2023;37(12):2517–25.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.3390/ph16040526","key":"1625_CR28","year":"2023","issue":"4","author":"E Campione","volume":"16","first-page":"526","unstructured":"Campione E, Lambiase S, Gaeta Shumak R, et al. A real-life study on the use of tildrakizumab in psoriatic patients. Pharmaceuticals (Basel). 2023;16(4):526.","article-title":null,"journal-title":"Pharmaceuticals (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.947","key":"1625_CR29","year":"2023","issue":"3","author":"S Khattri","volume":"89","first-page":"AB237","unstructured":"Khattri S, Gooderham M, Reich A, et al. The Psoriasis Study of Health Outcomes (PSoHO) in biologic-naive and -experienced patients: a post-hoc analysis of patients receiving treatment according to US labels. J Am Acad Dermatol. 2023;89(3):AB237.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18376","key":"1625_CR30","year":"2022","issue":"11","author":"A Pinter","volume":"36","first-page":"2087","unstructured":"Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087–100.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2133531","key":"1625_CR31","year":"2023","issue":"1","author":"CDB Elgaard","volume":"34","first-page":"2133531","unstructured":"Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2023;34(1):2133531.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR32","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Grabowski K, Narbutt J, Lesiak A, Skibińska M, Noweta M, editors. Real-world effectiveness of interleukin-23 inhibitors in plaque psoriasis in patients from a tertiary dermatology centre. Seville: European Academy of Dermatology and Venerology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1038/s41598-022-18790-9","key":"1625_CR33","year":"2022","issue":"1","author":"T Graier","volume":"12","first-page":"15078","unstructured":"Graier T, Weger W, Jonak C, et al. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep. 2022;12(1):15078.","article-title":null,"journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR34","year":"2023","issue":null,"author":"A Merchán","volume":"30","first-page":"A74","unstructured":"Merchán A, Lucía SC, Raquel FM, et al. Comparison of the effectiveness between interleukin-23 inhibitors for treatment of psoriasis in a third level hospital. Eur J Clin Pharm. 2023;30:A74.","article-title":null,"journal-title":"Eur J Clin Pharm","doi-asserted-by":null},{"DOI":"10.1111/dth.15793","key":"1625_CR35","year":"2022","issue":"11","author":"F Ricceri","volume":"35","first-page":"e15793","unstructured":"Ricceri F, Chiricozzi A, Peris K, Prignano F. Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: a multicentric retrospective study. Dermatol Ther. 2022;35(11):e15793.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2081655","key":"1625_CR36","year":"2022","issue":"6","author":"M Megna","volume":"33","first-page":"2813","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–20.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.14979","key":"1625_CR37","year":"2022","issue":"3","author":"A Ruggiero","volume":"47","first-page":"561","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–7.","article-title":null,"journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"TREMFYA® (guselkumab) injection, for subcutaneous or intravenous use. Full Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR39","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"SKYRIZI® (risankizumab-rzaa) injection, for subcutaneous or intravenous use. Full Prescribing Information. North Chicago, IL: AbbVie Inc.; 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR40","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Rodica O, Ana-Maria C, Maria-Magdalena C, editors. IL23 inhibitors in psoriasis-case series. Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR41","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Alarcon SS, Ramos FJM, Diaz JM, et al, editors. Tildrakizumab in the treatment of moderate to severe plaque psoriasis: 52 weeks of real-world experience in the Valencian Community. Milan: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.36849/jdd.6830","key":"1625_CR42","year":"2023","issue":"8","author":"J Bagel","volume":"22","first-page":"766","unstructured":"Bagel J, Novak K, Nelson E. Tildrakizumab in combination with topical halcinonide 0.1% ointment for treating moderate to severe plaque psoriasis. J Drugs Dermatol. 2023;22(8):766–72.","article-title":null,"journal-title":"J Drugs Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR43","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Baratta S, Mortato E, Viola R, Poli MA, De Caro AP, Loconsole F, editors. Real-life experience with tildrakizumab in our clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR44","year":"2023","issue":"suppl 4","author":"G Becher","volume":"188","first-page":"ljad113. 35","unstructured":"Becher G, Stephen K, McInnes A, et al. Clinical priorities when treating psoriasis: insights from a real-world data study of tildrakizumab. Br J Dermatol. 2023;188(suppl 4):ljad113. 35.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2022.06.826","key":"1625_CR45","year":"2022","issue":"3","author":"N Bhatia","volume":"87","first-page":"AB199","unstructured":"Bhatia N, Heim J, Torres M, Beute P, Rozzo SJ, Vasquez JG. Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: week 28 interim analysis of a phase 4 study. J Am Acad Dermatol. 2022;87(3):AB199.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jval.2023.03.2445","key":"1625_CR46","year":"2023","issue":"6","author":"N Bhatia","volume":"26","first-page":"S57","unstructured":"Bhatia N, Vasquez JG, Schenkel B, Rozzo SJ, Heim J. Real-world effectiveness and safety in a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis. Value Health. 2023;26(6):S57.","article-title":null,"journal-title":"Value Health","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.865","key":"1625_CR47","year":"2023","issue":"3","author":"N Bhatia","volume":"89","first-page":"AB216","unstructured":"Bhatia N, Vasquez JG, Schenkel B, Rozzo SJ, Heim J. Real-world effectiveness of tildrakizumab in a phase 4 study in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB216.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2023.2200872","key":"1625_CR48","year":"2023","issue":"1","author":"N Bhatia","volume":"34","first-page":"2200872","unstructured":"Bhatia N, Heim J, Schenkel B, Vasquez JG. Quality of life and patient-reported symptoms in a phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: week 28 interim analysis. J Dermatolog Treat. 2023;34(1):2200872.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.36849/jdd.7471","key":"1625_CR49","year":"2023","issue":"8","author":"J Heim","volume":"22","first-page":"754","unstructured":"Heim J, Vasquez JG, Schenkel B, Bhatia N. Real-world effectiveness and safety of tildrakizumab in patients with moderate-to-severe psoriasis: week 28 interim analysis of a phase 4 study. J Drugs Dermatol. 2023;22(8):754–60.","article-title":null,"journal-title":"J Drugs Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.344","key":"1625_CR50","year":"2023","issue":"3","author":"JG Vasquez","volume":"89","first-page":"AB85","unstructured":"Vasquez JG, Bhatia N, Schenkel B, Rozzo SJ, Heim J. Safety of tildrakizumab in a phase 4 real-world study in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB85.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.819","key":"1625_CR51","year":"2023","issue":"3","author":"J Heim","volume":"89","first-page":"AB204","unstructured":"Heim J, Vasquez JG, Rozzo SJ, Schenkel B, Bhatia N. Patients’ quality of life in a phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB204.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.36849/JDD.6828","key":"1625_CR52","year":"2022","issue":"8","author":"A Brunasso","volume":"21","first-page":"914","unstructured":"Brunasso A. Nail psoriasis improvement during tildrakizumab therapy: a real-life experience. J Drugs Dermatol. 2022;21(8):914–6.","article-title":null,"journal-title":"J Drugs Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR53","year":"2021","issue":null,"author":"M Burlando","volume":"10","first-page":"2021-6-8","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:2021-6–8.","article-title":null,"journal-title":"Drugs Context","doi-asserted-by":null},{"DOI":null,"key":"1625_CR54","year":"2022","issue":"18","author":"M Burlando","volume":"26","first-page":"6772","unstructured":"Burlando M, Maul JT, Salvi I, et al. Psoriasis patients’ characteristics associated with high PASI response to tildrakizumab: an international dual center study. Eur Rev Med Pharmacol Sci. 2022;26(18):6772–6.","article-title":null,"journal-title":"Eur Rev Med Pharmacol Sci","doi-asserted-by":null},{"DOI":null,"key":"1625_CR55","year":"2022","issue":"6","author":"G Caldarola","volume":"35","first-page":"e15488","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":null},{"DOI":null,"key":"1625_CR56","year":"2023","issue":null,"author":"S Lambiase","volume":null,"first-page":null,"unstructured":"Lambiase S, Shumak RG, Lanna C, et al. A real life clinical experience of tildrakizumab in patients affected by psoriasis and metabolic comorbidities. Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR57","year":"2022","issue":null,"author":"A Costanzo","volume":null,"first-page":null,"unstructured":"Costanzo A, Cuccia A, Daudén E, et al. Tildrakizumab improves symptoms of pruritus, pain, and scaling in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Milan: European Academy of Dermatology and Venereology Congress; 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR58","year":"2023","issue":null,"author":"A Costanzo","volume":null,"first-page":null,"unstructured":"Costanzo A, Cuccia A, Daudén E, et al. Super responders to tildrakizumab treatment in moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR59","year":"2023","issue":null,"author":"A Costanzo","volume":null,"first-page":null,"unstructured":"Costanzo A, Cuccia A, Daudén E, et al. Tildrakizumab demonstrates high efficacy and a favourable safety profile in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Singapore: World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR60","year":"2023","issue":null,"author":"A Costanzo","volume":null,"first-page":null,"unstructured":"Costanzo A, Cuccia A, Dauden E, et al. Tildrakizumab demonstrates high efficacy regardless of baseline characteristics in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.19229","key":"1625_CR61","year":"2023","issue":"10","author":"A Costanzo","volume":"37","first-page":"2004","unstructured":"Costanzo A, Llamas-Velasco M, Fabbrocini G, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023;37(10):2004–15.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.5826/dpc.1304a215","key":"1625_CR62","year":"2023","issue":"4","author":"EV Di Brizzi","volume":"13","first-page":"e2023215","unstructured":"Di Brizzi EV, Buononato D, Benvenuto P, et al. Effectiveness and safety after a switch to tildrakizumab: a real world multicenter Italian study in psoriasis. Dermatol Pract Concept. 2023;13(4):e2023215.","article-title":null,"journal-title":"Dermatol Pract Concept","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR63","year":"2023","issue":null,"author":"K Drerup","volume":null,"first-page":null,"unstructured":"Drerup K, Seemann C, Gerdes S, Mrowiet U. Tildrakizumab in psoriasis: extended real world data from a prospective cohort study (KTC). Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1159/000519924","key":"1625_CR64","year":"2022","issue":"4","author":"KA Drerup","volume":"238","first-page":"615","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615–9.","article-title":null,"journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR65","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Escalas J, Palos CM, Ramos AL, editors. Tildrakizumab experience in real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR66","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Fornons-Servent R, Ferrer AL, Vilarrasa E, et al editors. Real-world evidence of effectiveness and safety of tildrakizumab in patients with moderate to severe psoriasis from 8 hospitals. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.3390/jcm11092631","key":"1625_CR67","year":"2022","issue":"9","author":"M Galluzzo","volume":"11","first-page":"2631","unstructured":"Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631.","article-title":null,"journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":"10.1002/jvc2.65","key":"1625_CR68","year":"2023","issue":"1","author":"A Gambardella","volume":"2","first-page":"52","unstructured":"Gambardella A, Licata G, De Rosa A, Calabrese G, Alfano R, Argenziano G. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. JEADV Clin Pract. 2023;2(1):52–8.","article-title":null,"journal-title":"JEADV Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.15818","key":"1625_CR69","year":"2022","issue":"11","author":"L Mastorino","volume":"35","first-page":"e15818","unstructured":"Mastorino L, Cariti C, Susca S, et al. Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement. Dermatol Ther. 2022;35(11):e15818.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR70","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Maul J-T, Steinmann S, Rosset N, et al editors. Management of moderate-to-severe psoriasis with tildrakizumab: first real-world-evidence results in a Swiss patient cohort from the SDNTT registry. Geneva: Schweizerische Gesellschaft für Dermatologie und Venerologie; 2021.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.18594","key":"1625_CR71","year":"2023","issue":"1","author":"A Narcisi","volume":"37","first-page":"93","unstructured":"Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study—IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR72","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Rodriguez Fernandez-Freire L, Ortiz J, Hernandez JC, Morillo M, Barabash R, Conejo-Mir J, editors. Tildrakizumab: efficacy and safety in mid-term (52 weeks) on real clinical practice in 32 patients with moderate-to-severe psoriasis. Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/dth.15941","key":"1625_CR73","year":"2022","issue":"12","author":"A Ruggiero","volume":"35","first-page":"e15941","unstructured":"Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S402183","key":"1625_CR74","year":"2023","issue":null,"author":"A Ruggiero","volume":"16","first-page":"529","unstructured":"Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529–36.","article-title":null,"journal-title":"Clin Cosmet Investig Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm11175098","key":"1625_CR75","year":"2022","issue":"17","author":"R Ruiz-Villaverde","volume":"11","first-page":"5098","unstructured":"Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, Font-Ugalde P, Galan-Gutierrez M. Tildrakizumab: efficacy, safety and survival in mid-term (52 weeks) in three tertiary hospitals in Andalucia (Spain). J Clin Med. 2022;11(17):5098.","article-title":null,"journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR76","year":"2023","issue":null,"author":"M Augustin","volume":null,"first-page":null,"unstructured":"Augustin M, Sommer R, Reguiai Z, et al. Real-world effectiveness, quality of life, and treatment satisfaction with tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR77","year":"2023","issue":null,"author":"U Mrowietz","volume":null,"first-page":null,"unstructured":"Mrowietz U, Sommer R, Reguiai Z, et al. Real-world safety of tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR78","year":"2023","issue":null,"author":"R Sommer","volume":null,"first-page":null,"unstructured":"Sommer R, Augustin M, Reguiai Z, et al. Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data of the phase IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR79","year":"2022","issue":null,"author":"A Tsianakas","volume":null,"first-page":null,"unstructured":"Tsianakas A, Ostendorf R, Diemert S, Asadullah K. Tildrakizumab improves quality of life in patients with moderate-to-severe chronic plaque psoriasis in a real-life setting. Milan: European Academy of Dermatology and Venereology Congress; 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.18572","key":"1625_CR80","year":"2023","issue":"1","author":"A Tsianakas","volume":"37","first-page":"85","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37(1):85–92.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR81","year":"2023","issue":null,"author":"A Tsianakas","volume":null,"first-page":null,"unstructured":"Tsianakas A, Kirsch A, Petri M. Sustained efficacy and safety of tildrakizumab over 2 years in patients with moderate to severe plaque psoriasis in routine clinical practice: interim results in week 100 from the non-interventional, prospective, multicenter study TILOT. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR82","year":"2023","issue":null,"author":"A Tsianakas","volume":null,"first-page":null,"unstructured":"Tsianakas A, Kirsch A, Schwichtenberg U. Tildrakizumab improves signs and symptoms in patients with moderate to severe plaque psoriasis in a realworld setting: a holistic approach. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1177/24755303221077211","key":"1625_CR83","year":"2022","issue":"2","author":"NW Wei","volume":"7","first-page":"55","unstructured":"Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7(2):55–9.","article-title":null,"journal-title":"J Psoriasis Psoriatic Arthritis","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1625"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Dermatology and Therapy"],"reference-count":83,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":83,"short-container-title":["Dermatol Ther (Heidelb)"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1007/s13555-025-01625-6","is_oa":true,"title":"Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-07","best_oa_location":{"url":"https://link.springer.com/content/pdf/10.1007/s13555-025-01625-6.pdf","pmh_id":null,"url_for_pdf":"https://link.springer.com/content/pdf/10.1007/s13555-025-01625-6.pdf","url_for_landing_page":"https://doi.org/10.1007/s13555-025-01625-6"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"warning","value":"Comparative results versus guselkumab and risankizumab are qualitative without effect sizes.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"warning","value":"Design classification reflects a meta-analysis of real-world observational studies with expected heterogeneity.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"warning","value":"Safety is summarized as 'low rates' without absolute numbers in the abstract.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"warning","value":"Total patient N is not reported in the abstract; only the number of studies is given.","value_numeric":null}],"summaries":{"what_studied":"A systematic review and meta-analysis of real-world studies evaluated tildrakizumab for adults with chronic moderate-to-severe plaque psoriasis, including comparisons with guselkumab and risankizumab. Outcomes were PASI, PGA, %BSA, DLQI, and safety at 12–16, 24–28, and 36–52 weeks across 37 studies (45 publications).","key_result":"From baseline to 36–52 weeks, mean PASI fell from 12.81 (95% CI 11.69–13.92) to 1.62 (1.03–2.20), %BSA from 16.21% (13.72–18.70) to 3.27% (1.26–5.28), PGA from 3.18 (2.89–3.47) to 0.70 (0.08–1.33), and DLQI from 14.59 (12.32–16.87) to 1.83 (0.84–2.82), reflecting 78–87% improvement, with low AE, SAE, TRAE, and WDAE rates. Effectiveness and safety were similar to guselkumab and risankizumab.","limitations":"Heterogeneity and potential bias across real-world observational studies; English-language restriction; follow-up limited to about 1 year.","practice_takeaway":"In routine care, tildrakizumab yields large, sustained improvements in disease severity and quality of life over up to 1 year with few safety concerns, and its performance appears comparable to guselkumab and risankizumab."}},{"doi":"10.1111/ijd.70092","pmid":"41115146","title":"Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis","journal_title":"International Journal of Dermatology","journal_issn":"0011-9059","published_at":"2025-10-20T00:00:00.000Z","url":"https://doi.org/10.1111/ijd.70092","source_score":15,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-25","doi":"10.1111/ijd.70092","days":"14","issn":"0011-9059","rank":"9","field":"Clinical Medicine","score":"15","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/ijd.70092","title":"Efficacy of Biologics for the Treatment of Moderate-To-Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta-Analysis.","journal":"International journal of dermatology","methods":"","results":"","abstract":"$32","keywords":["Asian population","SOC","biologics","meta‐analysis","psoriasis","skin of color","systematic review","tildrakizumab"],"pubmed_id":"41115146","conclusions":"","publication_date":"2025-10-20T00:00:00"},"crossref":{"DOI":"10.1111/ijd.70092","URL":"https://doi.org/10.1111/ijd.70092","ISSN":["0011-9059","1365-4632"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.70092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis"],"author":[{"given":"Akihiko","family":"Asahina","sequence":"first","affiliation":[{"name":"The Jikei University School of Medicine Tokyo Japan"}]},{"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Robyn","family":"Kendall","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Gopika","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Paul","family":"Serafini","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Asif","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc. Princeton New Jersey USA"}]},{"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc. Princeton New Jersey USA"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Beijing China"}]}],"funder":[{"id":[{"id":"10.13039/501100013671","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,10,20]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-20T15:39:01Z","timestamp":1760974741000,"date-parts":[[2025,10,20]]},"indexed":{"date-time":"2025-10-20T16:38:54Z","timestamp":1760978334520,"date-parts":[[2025,10,20]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000,"date-parts":[[2025,10,20]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/ijd.70092"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-05-15"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-23"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-20"}],"deposited":{"date-time":"2025-10-20T15:39:04Z","timestamp":1760974744000,"date-parts":[[2025,10,20]]},"issn-type":[{"type":"print","value":"0011-9059"},{"type":"electronic","value":"1365-4632"}],"published":{"date-parts":[[2025,10,20]]},"publisher":"Wiley","reference":[{"DOI":"10.1038/nature05663","key":"e_1_2_10_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3386","key":"e_1_2_10_3_1","year":"2020","issue":"3","author":"Reid C.","volume":"100","first-page":null,"unstructured":null,"article-title":"Psoriasis and Treatment: Past, Present and Future Aspects","journal-title":"Acta Dermato‐Venereologica","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2015.02.003","key":"e_1_2_10_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2010.11.055","key":"e_1_2_10_5_1","year":"2011","issue":"1","author":"American Academy of Dermatology Work Group","volume":"65","first-page":"137","unstructured":null,"article-title":"Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 6. Guidelines of Care for the Treatment of Psoriasis and Psoriatic Arthritis: Case‐Based Presentations and Evidence‐Based Conclusions","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12325-022-02065-w","key":"e_1_2_10_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.4029","key":"e_1_2_10_7_1","year":"2020","issue":"3","author":"Armstrong A. W.","volume":"156","first-page":"258","unstructured":null,"article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta‐Analysis","journal-title":"JAMA Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0220868","key":"e_1_2_10_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.17448","key":"e_1_2_10_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-022-00843-6","key":"e_1_2_10_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/jrsm.1432","key":"e_1_2_10_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.l4898","key":"e_1_2_10_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/0272989X12458724","key":"e_1_2_10_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/sim.6475","key":"e_1_2_10_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1467-9868.00353","key":"e_1_2_10_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“HUMIRA (Adalimumab) Prescribing Information ”(2021) http://www.rxabbvie.com/pdf/humira.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“CIMZIA (Cetrolizumab Pegol) Prescribing Information ”(2024) https://www.cimziahcp.com/full‐prescribing‐info.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Remicade (Infliximab) Prescribing Information ”(2021) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/REMICADE‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Bimzelx (Bimekizumab) Prescribing Information ”(2024) https://www.bimzelxhcp.com/prescribing‐information.pdf?_gl=1%2Athjj0v%2A_ga%2ANDUxMjQ1OTQ3LjE3Mjk2Njc5MjA.%2A_ga_CKX2D73W9W%2AMTczMTQwMjY0Ni41MS4xLjE3MzE0MDQ3MTguMC4wLjA.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“SILIQ (Brodalumab) Prescribing Information ”(2024) https://www.bauschhealth.com/Portals/25/Pdf/PI/Siliq‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“TALTZ (Ixekizumab) Prescribing Information ”(2024) http://uspl.lilly.com/taltz/taltz.html?s=pi.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Cosentyx (Secukinumab) Prescribing Information ”(2024) https://www.novartis.com/us‐en/sites/novartis_us/files/cosentyx.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Tremfya (Guselkumab) Prescribing Information ”(2024) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/TREMFYA‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Skyrizi (Risankizumab) Prescribing Information ”(2024) https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“ILUMYA (Tildrakizumab) Prescribing Information ”(2022) https://www.ilumya.com/Sun_Pharma_ILUMYA_US_Prescribing_Information_.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Stelara (Ustekinumab) Prescribing Information ”(2019) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/STELARA‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/j.1346-8138.2009.00748.x","key":"e_1_2_10_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.13746","key":"e_1_2_10_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00520-0","key":"e_1_2_10_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Clinicaltrials.gov “NCT03051217. A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis ”https://clinicaltrials.gov/study/NCT03051217.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jdermsci.2010.04.014","key":"e_1_2_10_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_32_1","year":"2012","issue":"11","author":"Yang H. Z.","volume":"125","first-page":"1845","unstructured":null,"article-title":"Infliximab Monotherapy for Chinese Patients With Moderate to Severe Plaque Psoriasis: A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Trial","journal-title":"Chinese Medical Journal","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Clinicaltrials.gov “NCT01177800. A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque‐Type Psoriasis ”(2025) https://clinicaltrials.gov/study/NCT01177800.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s13555-022-00883-y","key":"e_1_2_10_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdermsci.2015.10.009","key":"e_1_2_10_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15733","key":"e_1_2_10_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.13927","key":"e_1_2_10_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/JD9.0000000000000244","key":"e_1_2_10_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.12668","key":"e_1_2_10_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.13900","key":"e_1_2_10_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/CM9.0000000000001163","key":"e_1_2_10_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14504","key":"e_1_2_10_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14941","key":"e_1_2_10_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15789","key":"e_1_2_10_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/CM9.0000000000002873","key":"e_1_2_10_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdermsci.2011.05.005","key":"e_1_2_10_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1346-8138.2011.01347.x","key":"e_1_2_10_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_48_1","year":"2013","issue":"2","author":"Zhu X.","volume":"12","first-page":"166","unstructured":null,"article-title":"Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque‐Type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(17)31279-5","key":"e_1_2_10_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19866","key":"e_1_2_10_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_51_1","year":"2021","issue":null,"author":"Burlando M.","volume":"10","first-page":null,"unstructured":null,"article-title":"Treatment of Moderate‐To‐Severe Plaque Psoriasis With Tildrakizumab in the Real‐Life Setting","journal-title":"Drugs in Context","doi-asserted-by":null},{"DOI":"10.1111/jdv.19229","key":"e_1_2_10_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15763","key":"e_1_2_10_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.10.017","key":"e_1_2_10_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.042","key":"e_1_2_10_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.041","key":"e_1_2_10_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)31713-6","key":"e_1_2_10_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_58_1","year":"2023","issue":"7","author":"Sbidian E.","volume":"7","first-page":null,"unstructured":null,"article-title":"Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta‐Analysis","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":"10.1007/s13555-025-01423-0","key":"e_1_2_10_59_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.xjidi.2024.100261","key":"e_1_2_10_60_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/ijd.70092"],"article-number":"ijd.70092","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["International Journal of Dermatology"],"reference-count":59,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,20]]},"references-count":59,"short-container-title":["Int J Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/ijd.70092","is_oa":false,"title":"Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis","updated":"2025-10-21T16:47:13+00:00","published_date":"2025-10-20","best_oa_location":null}},"created_at":"2025-10-27T13:37:43.000Z","updated_at":"2025-11-05T07:41:18.588Z","tags":[{"paper_doi":"10.1111/ijd.70092","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Comparative effect sizes and credible intervals are not provided; “comparable” at Week 28 is qualitative in the abstract.","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Safety results were within scope but not summarized in the abstract.","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Total number of participants across trials is not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and Bayesian network meta-analysis of 19 randomized trials from China, Japan, Korea, and Taiwan comparing tildrakizumab with 10 other biologics in adult Asian patients with moderate-to-severe plaque psoriasis over 12–28 weeks, using PASI 75/90/100 and PGA 0/1.","key_result":"At Week 12, tildrakizumab showed lower efficacy than other biologics. From Weeks 12 to 28, PASI responses with tildrakizumab increased from 60.77%→81.84% (PASI 75), 38.54%→71.23% (PASI 90), and 6.97%→22.64% (PASI 100); by Week 28, efficacy was comparable to TNFα, IL-17, IL-12/23, and other IL-23 inhibitors.","practice_takeaway":"For Asian adults starting tildrakizumab, expect slower early clearance by 12 weeks but marked gains by 28 weeks, reaching parity with other biologics. Its sustained improvement and low dosing frequency support it as an effective option for moderate-to-severe plaque psoriasis."}}],"initialOffset":6,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"tildrakizumab"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"tildrakizumab"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"tildrakizumab"}}}]]

Papers